MC4R and myeloid sarcoma: Furthermore, we showed that in vitro activation of the MC4R with setmelanotide ameliorated a reactive phenotype in astrocytes, and observed that astrocyte conditioned medium from setmelanotide stimulated astrocytes skewed macrophages toward an anti-inflammatory phenotype, which could limit ongoing damage, and eventually reduce clinical disability in MS (22, 23).